Deficiência de anticorpos específicos antipolissacarídeos
Specific polysaccharide antibody deficiency
Wilma Carvalho Neves Forte; Renata Yumi Lima Konichi; Fernanda Mezzacapa Sousa; Tainá Mosca; Almerinda Maria Rego; Ekaterini Simões Goudouris
Resumo
A deficiência de anticorpos específicos antipolissacarídeos é um dos erros inatos da imunidade predominantemente de anticorpos, destacando-se entre os defeitos mais frequentes. É caracterizada por uma permanência de imaturidade da resposta imunológica a antígenos polissacarídeos, estando normais linfócitos B, classes e subclasses de imunoglobulinas. O paciente apresenta maior suscetibilidade a infecções por bactérias encapsuladas, especialmente Streptococcus pneumoniae e Haemophilus influenzae. As principais manifestações clínicas são otites, sinusites, traqueobronquites e pneumonias de repetição; pode haver meningite pneumocócica e septicemia. A investigação é feita por titulação de anticorpos antipolissacarídeos antes e após a aplicação da vacina pneumocócica não conjugada. Até dois anos, há imaturidade fisiológica desse setor da imunidade, por isso, o diagnóstico não pode ser feito antes desta idade. O tratamento, além de antibiótico precoce em vigência de quadros infecciosos, inclui antibióticos profiláticos, aplicação de vacina conjugada com proteínas e/ou reposição de imunoglobulina humana endovenosa ou subcutânea. O diagnóstico e o tratamento precoce melhoram a qualidade de vida do paciente, diminuindo o risco de sequelas e até de óbito por infecção, e quando não são precoces, é possível que haja sequelas como bronquiectasias, hipoacusia ou danos neurológicos.
Palavras-chave
Abstract
Specific polysaccharide antibody deficiency is an inborn error of immunity predominantly affecting antibodies, being one of the most frequent primary immunodeficiencies of childhood. It is characterized by persistent immaturity of the immune response to polysaccharide antigens, with normal levels of B lymphocytes, immunoglobulin classes and subclasses. Patients are more susceptible to infections by encapsulated bacteria, especially Streptococcus pneumoniae and Haemophilus influenzae. The main clinical manifestations are recurrent otitis, sinusitis, tracheobronchitis and pneumonia; there may be pneumococcal meningitis and septicemia. The investigation is done by dosages of polysaccharide antibodies before and after unconjugated pneumococcal vaccination. As this area of immunity is physiologically immature until two years of age, diagnosis cannot be made earlier. Treatment, in addition to antibiotics as soon as infections are detected, includes prophylactic antibiotic therapy, use of pneumococcal vaccine conjugated to protein and/or replacement of intravenous or subcutaneous human immunoglobulin. Early diagnosis and treatment improve patients’ quality of life, reducing the risk of sequelae and even death from infection, while lack of early measures can lead to sequelae such as bronchiectasis, hearing loss and neurological damage.
Keywords
Referências
1. Al-Herz W, Bousfiha A, Casanova JL, Chapel H, Conley ME, Cunningham-Rundles C, et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency. Front Immunol. 2011;2:1-26.
2. Uddin S, Borrow R, Haeney MR, Moran A, Warrington R, Balmer P, et al. Total and serotype-specific pneumococcal antibody titles in children with normal and abnormal humoral immunity. Vaccine. 2006;24(27-28):5637-44.
3. Wahn U, Moises A. Calderon, Pascal Demoly. Real-life clinical practice and management of polysensitized patients with respiratory allergies: a large, global survey of clinicians prescribing allergen immunotherapy. Expert Rev Clin Immunol. 2017;13:283-9.
4. Kutukculer N, Karaca NE, Demircioglu O, Aksu G. Increases in serum immunoglobulins to age-related normal levels in children with IgA and/or IgG subclass deficiency. Pediatr Allergy Immunol. 2007;18:167-3. Deficiência de anticorpos específicos antipolissacarídeos – Forte WCN et al.
5. Ambrosino DM, Siber GR, Chilmonczyk BA, Jernberg JB, Finberg RW. An immunodeficiency characterized by impaired antibody responses to polysaccharides. N Engl J Med. 1987;316:790-3.
6. Granoff DM, Schackelford PG, Suarez BK, Nahm MH, Cates KL, Murphy TV, et al. Haemophilus influenza type B disease in children vaccinated with type B polyssacacharide vaccine. N Engl J Med. 1986;315:1584-90.
7. Perez E, Bonilla FA, Orange JS, Ballow M. Specific antibody deficiency: controversies in diagnosis and management. Front Immunol. 2017;8:586.
8. Notarangelo LD, Fischer A, Geha RS, Casanova JL, Chapel H, Conley ME, et al. Primary immunodeficiencies: 2009 update. J. Allergy Clin Immunol. 2010; 125(3):771-3.
9. Stiehm ER, Casillas AM, Finkeslstein JZ. Immunodeficiency disorders: general considerations. In: Stiehm ER, Ochs HD, Winkelstein JA. Immunological disorders in infants and children. 5ª ed. Philadelphia: Elsevier Saunders; 2004. p. 289-355.
10. Boyle J. Population prevalence of diagnosed primary immunodeficiency in the US. J Clin Immunol. 2007;5(27):497-502.
11. Bousfiha AA, Jeddane L, Ailal F, Benhsaien I, Mahlaoui N, Casanova JL, Abel L. Primary immunodeficiency diseases worldwide: more common than generally thought. J Clin Immunol. 2013;33(1):1-7.
12. Mahlaoui N, Gathmann B, Kindle G, Ehl S, and the ESID Society. The European Society for Immunodeficiencies (ESID) Registry: recent advancements in the epidemiology of Primary Immunodeficiencies and how does that translate in clinical care. Int J Public Health. 2014;1(S4):25-7.
13. Leiva LE, Zelasco M, Oleastro M, Carneiro-Sampaio M, CondinoNeto A, Costa-Carvalho BT, et al. Primary immunodeficiency disease in Latin America: the second report of the LAGID directory. J Clin Immunol. 2007;27(1):101-8.
14. Roxo-Júnior P. Imunodeficiências primárias: aspectos relevantes para o pneumologista. J Bras Pneumol. 2009;35:1008-17.
15. Orange JS, Seeborg FO, Marcia B, Scalchunes C, Hernandez-Trujillo V. Family physician perspectives on primary immunodeficiency diseases. Front Med. 2016;3:12.
16. Serpa FS, Guidacci AF, Rubini NP. O atendimento médico de pacientes com doenças imunoalérgicas no Brasil: reflexões e propostas para a melhoria. Arq Asma Alerg Imunol. 2017;1(4):327‑34.
17. Schatorjé EJH. The challenge of immunoglobulin-G subclass deficiency and specific polysaccharide antibody deficiency - a dutch pediatric cohort study. J Clin Immunol. 2016;36(2):141-8.
18. Errante PR, Franco JL, Espinosa-Rosales FJ, Sorensen R, CondinoNeto A. Advances in primary immunodeficiency diseases in Latin America: epidemiology, research, and perspectives. Ann N Y Acad Sci. 2012;1250:62-72.
19. LaCross NC, Marrs CF, Gilsdorf JR. Population structure in nontypeable Haemophilus influenzae. Infect Genet Evol. 2013;14:125-36.
20. Janeway CA, Travers P, Walport Mark, Shlomchik M. Imunidade adaptativa contra a infecção. In: Janeway CA, Travers P, Walport Mark, Shlomchik M. Imunobiologia - o sistema imune na saúde e na doença. 6ª ed. Porto Alegre: Artmed; 2007. p. 409-59.
21. Forte WCN. Fagócitos. In: Forte WCN. Imunologia do básico ao aplicado. 3ª ed. São Paulo: Editora Atheneu; 2015. p. 15-24.
22. Weintraub A. Immunology of bacterial polysaccharide antigens. Carbohydr Res. 2003;338(23):2539-47.
23. Obukhanych TV, Nussenzweig MC. T-independent type II immune responses generate memory B cells. J Exp Med. 2006;203(2):305‑10.
24. Hyams C, Camberlein E, Cohen JM, Bax K, Brown JS. The Streptococcus pneumoniae capsule inhibits complement activity and neutrophil phagocytosis by multiple mechanisms. Infect Immun. 2010;78:704-15.
25. Forte WCN. Sistema complemento. In: Forte WCN. Imunologia do básico ao aplicado. 3ª ed. São Paulo: Editora Atheneu; 2015. p. 25-34.
26. Ferreyra PN, Costa-Carvalho B, Orii N, Carneiro-Sampaio MMS. A síndrome de deficiência de anticorpos com imunoglobulinas normais não está relacionada ao aumento de número de células B CD19+CD5+. Rev bras alerg imunopatol. 2004;27(2):36-46.
27. Forte WCN. Imunoglobulinas. In: Forte WCN. Imunologia do básico ao aplicado. 3ª ed. São Paulo: Editora Atheneu; 2015. p. 51-64.
28. Carr TF, Koterba AP, Chandra R, Grammer LC, Conley DB, Harris KE, et al. Characterization of specific antibody deficiency in adults with medically refractory chronic rhinosinusitis. Am J Rhinol Allergy. 2011;25(4):241-4.
29. Kashani S, Carr TF, Grammer LC, Schleimer RP, Hulse KE, Kato A, et al. Clinical characteristics of adults with chronic rhinosinusitis and specific antibody deficiency. J Allergy Clin Immunol Pract. 2015;3(2):236-42.
30. Ocampo CJ, Peters AT. Antibody deficiency in chronic rhinosinusitis: epidemiology and burden of illness. Am J Rhinol Allergy. 2013;27(1):34-8.
31. Kadioglu A, Weiser JN, Paton JC, Andrew PW. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat Pub Group Microbiol. 2008;6:288‑301.
32. Bossuyt X, Moens L, van Hoeyveld E, Jeurissen A, Bogaert G, Sauer K, et al. Coexistence of (partial) immune defects and risk of recurrent respiratory infections. Clin Chem. 2007;53:124-30.
33. Cheng YK, Decker PA, O’Byrne MM, Weiler CR. Clinical and laboratory characteristics of 75 patients with specific polysaccharide antibody deficiency syndrome. Ann Allergy Asthma Immunol. 2006;97(3):306-11.
34. Condino-Neto A, Franco JL, Trujillo-Vargas C, Espinosa-Rosales FJ, Leiva LE, Rodriguez-Quiroz F, et al. Critical issues and needs in management of Primary Immunodeficiency diseases in Latin America. Allergol Immunopathol. 2011;3(1):45-51.
35. Stiehm RS. The four most common pediatric immunodeficiencies. J Immunotoxicol. 2008;5(2):227-34.
36. Sorensen RU, Leiva LE. Measurement of pneumococcal polysaccharide antibodies. J Clin Immunol. 2014;34(2):127-8.
37. Yoshioka CRM, Martinez MB, Brandileone MCC, Ragazzi SB, Guerra MLLS, Santos SR, et al. Análise de cepas de Streptococcus pneumoniae causadores de pneumonia invasiva: sorotipos e sensibilidade aos antimicrobianos. J Ped (Rio J). 2011;87:70-5.
38. Brazilian Group for Immunodeficiency [Internet]. Sinais de alerta para Imunodeficiência primária na criança e no adulto. Disponível em: http://www.bragid.org.br. Acessado em: 27/01/2018.
39. Beppu APK, Melardi JW, Gaudino VRR, Marina Santos MC, Menezes MCS, Forte WCN. Pneumonias em imunodeficiência comum variável após mudança de ambiente físico. J Allergy Immunol. 2015;3(3):93-8.
40. Divino PHA, Basilio JHC, Fabbri RMA, Polonio IB, Forte WCN. Bronquiectasia por imunodeficiência comum variável. J Bras Pneumol. 2015;41(5):482-4.
41. Vendrell M, de Gracia J, Rodrigo MJ, Cruz MJ, Alvarez A, Garcia M, et al. Antibody production deficiency with normal IgG levels in bronchiectasis of unknown etiology. Chest. 2005;127(1):197-204.
42. Costa-Carvalho BT, Wandalsen GF, Pulici G, Aranda CS, Solé D. Pulmonary complications in patients with antibody deficiency. Allergol Immunopathol. 2011;39(3):128-32.
43. Wall LA, Dimitriades VR, Sorensen RU. Specific antibody deficiencies. Immunol Allergy Clin North Am. 2015;35(4):659-70.
44. Boyle RJ, Le C, Balloch A, Tang ML. The clinical syndrome of specific antibody deficiency in children. Clin Exp Immunol. 2006;146(3):486‑92.
45. Bonilla FA, Khan DA, Ballas ZK, Chinen J, Frank MM, Hsu JT, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186‑205.
46. Parker AR, Allen S, Harding S. Concentration of anti-pneumococcal capsular polysaccharide IgM, IgG and IgA specific antibodies in adult blood donos. Pract Labor Med. 2016;5:1-5.
47. Borgers H, Jeruissen A, Flamaing J, Peetermans WE, Moens L, Verhaegen J, et al. Elderly subjects do not show impaired pneumococcal capsular polysaccharide serotype-specific antibody responses as assessed by a multiplexed bead assay. Clin Immunol. 2010;135:501-2.
48. Forte WCN. Imunodeficiências primárias. In: Forte WCN. Imunologia do básico ao aplicado. 3ª ed. São Paulo: Editora Atheneu; 2015. p. 221-48.
49. Paris K, Sorensen RU. Assessment and clinical interpretation of polysaccharide antibody responses. Ann Allergy Asthma Immunol. 2007;99(5):462-4.
50. Orange JS, Ballow M, Stiehm ER, Ballas ZK, Chinen J, De La Morena M, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2012 Sep;130(3 Suppl):S1-24.
51. Borgers H, Moens L, Picard C, Jeurissen A, Raes M, Sauer K, et al. Laboratory diagnosis of specific antibody deficiency to pneumococcal capsular polysaccharide antigens by multiplexed bead assay. Clin Immunol. 2010;134(2):198-205.
52. Moens L, Picard C, Shahrooei M, Wuyts G, Liston A, Fischer A, Bossuyt X. Different immunological pathways underlie the immune response to pneumococcal polysaccharides. J Clin Immunol. 2017;37(3):277-8.
53. Grumach AS. Imunodeficiências predominantemente humorais. In: Grumach AS. Alergia e imunologia na infância e na adolescência. 2ª ed. São Paulo: Editora Atheneu; 2009. p. 533-56.
54. Roux A, Schmole-Thoma B, Siber G, Hackell J, Kuhnke A, Ahlers N, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis. 2008;46:1015-23.
55. Turner AEB, Gerson JE, So HY, Krasznai DJ, Hilaire AJ, Gerson DF. Novel polysaccharide-protein conjugates provide an immunogenic 13-valent pneumococcal conjugate vaccine for S. pneumoniae. Synth Syst Biotechnol. 2017;2(1):49-58.
56. Rose MA, Schubert R, Strnad N, Zielen S. Priming of immunological memory by pneumococcal conjugate vaccine in children unresponsive to 23-valent polysaccharide pneumococcal vaccine. Clin Diagn Lab Immunol. 2005;12(10):1216-22.
57. Daniels CC, Rogers PD, Shelton CM. A review of pneumococcal vaccines: current polysaccharide vaccine recommendations and future protein antigens. J Pediatr Pharmacol Ther. 2016;21(1):27‑35.
58. Balloch A, Licciardi PV, Russell FM, Mulholland EK, Tang ML. Infants aged 12 months can mount adequate serotype-specific IgG responses to pneumococcal polysaccharide vaccine. J Allergy Clin Immunol. 2010;126(2):395-7.
59. Schütz K, Hughes RG, Parker A, Quinti I, Thon V, Cavaliere M, et al. Kinetics of IgM and IgA antibody response to 23-valent pneumococcal polysaccharide vaccinations in healthy subjects. J Clin Immunol. 2012;33(1):288-96.
60. Daly TM, Hill HR. Use and clinical interpretation of pneumococcal antibody measurements in the evaluation of humoral immune function. Clin Vaccine Immunol. 2015;22(2):48-152.
61. Klein DL, Martinez JE, Hickey MH, Hassouna F, Zaman K, Steinhoff M. Development and characterization of a multiplex bead-based immunoassay to quantify pneumococcal capsular polysaccharidespecific antibodies. Clin Vaccine Immunol. 2012;19(8):1276-82.
62. Elberse KE, Tcherniaeva I, Berbers GA, Schouls LM. Optimization and application of a multiplex bead-based assay to quantify serotypespecific IgG against Streptococcus pneumoniae polysaccharides: response to the booster vaccine after immunization with the pneumococcal 7-valent conjugate vaccine. Clin Vaccine Immunol. 2010;17(4):674-82.
63. Beck SC. Making sense of serotype-specific pneumococcal antibody measurements. Ann Clin Biochem. 2013;50(6):517-9.
64. Cavaliere FM, Milito C, Martini H, Schlesier M, Dräger R, Schütz K, et al. Quantification of IgM and IgA anti-pneumococcal capsular polysaccharides by a New ELISA Assay: a valuable diagnostic and prognostic tool for Common Variable Immunodeficiency. J Clin Immunol. 2013;33(4):838-46.
65. Barreto BAP, Sarinho ESC, Stefani GM, Chong-Neto HJ, Chiabai J. Alonso MLO, et al. Deficiência específica de anticorpo antipolissacarídeo de pneumococo e resposta humoral a vacinas pneumocócicas: atualização em diagnóstico. Arq Asma Alerg Imunol. 2014;1(50):253-60.
66. Goudouris, ES, Silva AMR, Ouricuri AL, Grumach AS, Condino A, Costa-Carvaho BT, e Grupo Brasileiro de IDPs da ASBAI. II Consenso Brasileiro sobre o uso de imunoglobulina humana em pacientes com imunodeficiências primárias. Einstein. 2017;15(1):1‑16.
67. Fried AJ, Bonilla FA. Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections. Clin Microbiol Ver. 2009;22(3):396-414.
68. Segundo GRS, Fernandes KP. Deficiência de anticorpos antipolissacarídicos: relato de casos. Rev bras alerg imunopatol. 2009;32(5):194-8.
69. García JM, Español T, Gurbindo MD, Casas C C. Update on the treatment of primary immunodeficiencies. Allergol Immunopatol. 2007;35(5):184-92.
70. Wood P. Immunotherapy for primary immunodeficiency diseases. Med Clin North Am. 2012;96(3):433-54.
71. Shehata N, Palda V, Bowen T, Haddad E, Issekutz TB, Mazer B, et al. The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline. Transfus Med Rev. 2010;24(1):S28-50.
72. Gardulf A, Nicolay U, Math D, Asensio O, Bernatowska E, Böck A, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol. 2004;114(4):936-42.
73. Goudouris ES, Silva AMR, Ouricuri AL, Grumach AS, Condino A, Costa-Carvalho BT, et al. Imunoglobulina humana por via subcutânea para imunodeficiências primárias. Braz J Allergy Immunol. 2014;2(4):127-8.
74. Leiva LE, Monjure H, Sorensen RU. Modulatory role of intravenous gammaglobulin (IgIV) on the in vitro antibody response to a pneumococcal polysaccharide antigen. J Clin Immunol. 2015;35(2):206-12.
75. Sewell WA, Kerr J, Behr-Gross ME, Peter HH. Kreuth Ig Working Group. European consensus proposal for immunoglobulin therapies. Eur J Immunol. 2014;44(8):2207-14.
76. Shabaninejad H, Asgharzadeh A, Rezaei N, Rezapoor A. A comparative study of intravenous immunoglobulin and subcutaneous immunoglobulin in adult patients with Primary Immunodeficiency Diseases: a systematic review and meta-analysis. Expert Rev Clin Immunol. 2016;12(5):595-602.
77. Misbah S, Sturzenegger MH, Borte M, Shapiro RS, Wasserman RL, Berger M, Ochs HD. Subcutaneous immunoglobulin: opportunities and outlook. Clin Exp Immunol. 2009;158(1):51-9.
78. Skoda-Smith S, Torgerson TR, Ochs HD. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease. Ther Clin Risk Manag. 2010;6:1-10.
Submetido em:
31/01/2019
Aceito em:
25/06/2019
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email